See What HealthDay Can Do For You
Contact Us

Hospital Delay Reduces Survival in Primary Angioplasty

Researchers find that speed of angioplasty determines survival versus clot-busting drugs

MONDAY, Oct. 30 (HealthDay News) -- The survival benefit of angioplasty over clot-busting drugs for ST-elevation myocardial infarction declines with increasing door-to-balloon times and also varies with patient characteristics, according to a study published online Oct. 30 in Circulation: Journal of the American Heart Association.

C. Michael Gibson, M.S., M.D., of Harvard Medical School in Boston, and colleagues subtracted median door-to-needle (DN) time from median door-to-balloon (DB) time at a hospital, using data from 192,509 patients at 645 hospitals. In the study, 126,909 patients were treated with clot-busting drugs and 65,600 had angioplasty.

The researchers found that the longer the DB-DN time, the greater the likelihood of mortality. The DB-DN time at which survival with angioplasty was no better than that of clot-busting drugs also depended on the patient's age, duration of symptoms, and location of the infarct.

"As indicated in the American College of Cardiology/American Heart Association guidelines, both the hospital-based primary percutaneous coronary intervention-related delay (DB-DN time) and patient characteristics should be considered when a reperfusion strategy is selected," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.